The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

Overview of attention for article published in Frontiers in oncology, February 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 11 Mendeley

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 6,551 followers.

📣 Original article: The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced #BreastCancer: Case Series and Review of the Literature 👨‍⚕️👩‍⚕️ @KrasniqiEriseld @agnese_fabbri 👉

12 Feb 2022

Reply Repost Favourite

New research: The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature: The recent addition of… https://t.co/ETaibYVevZ #o

09 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.